Loading…

Update on the treatment of type 2 diabetes mellitus

To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving nearnormal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different...

Full description

Saved in:
Bibliographic Details
Published in:World journal of diabetes 2016-09, Vol.7 (17), p.354-395
Main Authors: Juan Jose Marin-Penalver, Iciar Martin-Timon, Cristina Sevillano-Collantes, Francisco Javier del Canizo-Gomez
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c348t-885b105121c581c520e8e2e5606c221752ebab7a8b107b2208f56581ac04efbe3
cites
container_end_page 395
container_issue 17
container_start_page 354
container_title World journal of diabetes
container_volume 7
creator Juan Jose Marin-Penalver
Iciar Martin-Timon
Cristina Sevillano-Collantes
Francisco Javier del Canizo-Gomez
description To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving nearnormal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different treatments, both oral and injectable, available for the treatment of type 2 diabetes mellitus (T2DM). Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control. The aim of this review is to perform an update on the benefits and limitations of different drugs, both current and future, for the treatment of T2DM. Initial intervention should focus on lifesty lechanges. Moreover, changes in lifestyle have proven to be beneficial, but for many patients is a complication keep long term. Physicians should be familiar with the different types of existing drugs for the treatment of diabetes and select the most effective, safe and better tolerated by patients. Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized depending on thecharacteristics of each patient. This article reviews the treatments available for patients with T2DM, with an emphasis on agents introduced within the last decade.
doi_str_mv 10.4239/wjd.v7.i17.354
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5027002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>7000168841</cqvip_id><sourcerecordid>1823037043</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-885b105121c581c520e8e2e5606c221752ebab7a8b107b2208f56581ac04efbe3</originalsourceid><addsrcrecordid>eNpVkN1LwzAUxYMobsy9-igFX3xpzWeTvggy_IKBL-45pO3t1tE2XZNN9t8b2RwzcMmF-8u5JwehW4ITTln2-L0uk51MaiITJvgFGpOMqzhjQl2e9SM0dW6Nw-EiTVl2jUZUpilOMzFGbNGXxkNku8ivIPIDGN9C5yNbRX7fQ0SjsjY5eHBRC01T-627QVeVaRxMj_cELV5fvmbv8fzz7WP2PI8LxpWPlRI5wYJQUggVimJQQEGEzQWlRAoKucmlUYGSOaVYVSINpCkwhyoHNkFPB91-m7dQFsHWYBrdD3Vrhr22ptb_J1290ku70wJTiTENAg9HgcFutuC8bmtXhF-YDuzWaaIow0xizgKaHNBisM4NUJ3WEKx_w9YhbL2TOoStQ9jhwd25uRP-F20A7o-KK9stN3W3PDHBHCapUpywH2mrhm4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1823037043</pqid></control><display><type>article</type><title>Update on the treatment of type 2 diabetes mellitus</title><source>PMC (PubMed Central)</source><creator>Juan Jose Marin-Penalver;Iciar Martin-Timon;Cristina Sevillano-Collantes;Francisco Javier del Canizo-Gomez</creator><creatorcontrib>Juan Jose Marin-Penalver;Iciar Martin-Timon;Cristina Sevillano-Collantes;Francisco Javier del Canizo-Gomez</creatorcontrib><description>To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving nearnormal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different treatments, both oral and injectable, available for the treatment of type 2 diabetes mellitus (T2DM). Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control. The aim of this review is to perform an update on the benefits and limitations of different drugs, both current and future, for the treatment of T2DM. Initial intervention should focus on lifesty lechanges. Moreover, changes in lifestyle have proven to be beneficial, but for many patients is a complication keep long term. Physicians should be familiar with the different types of existing drugs for the treatment of diabetes and select the most effective, safe and better tolerated by patients. Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized depending on thecharacteristics of each patient. This article reviews the treatments available for patients with T2DM, with an emphasis on agents introduced within the last decade.</description><identifier>ISSN: 1948-9358</identifier><identifier>EISSN: 1948-9358</identifier><identifier>DOI: 10.4239/wjd.v7.i17.354</identifier><identifier>PMID: 27660695</identifier><language>eng</language><publisher>United States: Baishideng Publishing Group Inc</publisher><subject>agents ; antidiabetic ; diabetes ; Future ; impairment ; Injectable ; mellitus ; Older ; Oral ; people ; Renal ; Review ; Treatment ; treatments ; Type</subject><ispartof>World journal of diabetes, 2016-09, Vol.7 (17), p.354-395</ispartof><rights>The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. 2016</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c348t-885b105121c581c520e8e2e5606c221752ebab7a8b107b2208f56581ac04efbe3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/71418X/71418X.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027002/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027002/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27660695$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Juan Jose Marin-Penalver;Iciar Martin-Timon;Cristina Sevillano-Collantes;Francisco Javier del Canizo-Gomez</creatorcontrib><title>Update on the treatment of type 2 diabetes mellitus</title><title>World journal of diabetes</title><addtitle>World Journal of Diabetes</addtitle><description>To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving nearnormal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different treatments, both oral and injectable, available for the treatment of type 2 diabetes mellitus (T2DM). Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control. The aim of this review is to perform an update on the benefits and limitations of different drugs, both current and future, for the treatment of T2DM. Initial intervention should focus on lifesty lechanges. Moreover, changes in lifestyle have proven to be beneficial, but for many patients is a complication keep long term. Physicians should be familiar with the different types of existing drugs for the treatment of diabetes and select the most effective, safe and better tolerated by patients. Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized depending on thecharacteristics of each patient. This article reviews the treatments available for patients with T2DM, with an emphasis on agents introduced within the last decade.</description><subject>agents</subject><subject>antidiabetic</subject><subject>diabetes</subject><subject>Future</subject><subject>impairment</subject><subject>Injectable</subject><subject>mellitus</subject><subject>Older</subject><subject>Oral</subject><subject>people</subject><subject>Renal</subject><subject>Review</subject><subject>Treatment</subject><subject>treatments</subject><subject>Type</subject><issn>1948-9358</issn><issn>1948-9358</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpVkN1LwzAUxYMobsy9-igFX3xpzWeTvggy_IKBL-45pO3t1tE2XZNN9t8b2RwzcMmF-8u5JwehW4ITTln2-L0uk51MaiITJvgFGpOMqzhjQl2e9SM0dW6Nw-EiTVl2jUZUpilOMzFGbNGXxkNku8ivIPIDGN9C5yNbRX7fQ0SjsjY5eHBRC01T-627QVeVaRxMj_cELV5fvmbv8fzz7WP2PI8LxpWPlRI5wYJQUggVimJQQEGEzQWlRAoKucmlUYGSOaVYVSINpCkwhyoHNkFPB91-m7dQFsHWYBrdD3Vrhr22ptb_J1290ku70wJTiTENAg9HgcFutuC8bmtXhF-YDuzWaaIow0xizgKaHNBisM4NUJ3WEKx_w9YhbL2TOoStQ9jhwd25uRP-F20A7o-KK9stN3W3PDHBHCapUpywH2mrhm4</recordid><startdate>20160915</startdate><enddate>20160915</enddate><creator>Juan Jose Marin-Penalver;Iciar Martin-Timon;Cristina Sevillano-Collantes;Francisco Javier del Canizo-Gomez</creator><general>Baishideng Publishing Group Inc</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160915</creationdate><title>Update on the treatment of type 2 diabetes mellitus</title><author>Juan Jose Marin-Penalver;Iciar Martin-Timon;Cristina Sevillano-Collantes;Francisco Javier del Canizo-Gomez</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-885b105121c581c520e8e2e5606c221752ebab7a8b107b2208f56581ac04efbe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>agents</topic><topic>antidiabetic</topic><topic>diabetes</topic><topic>Future</topic><topic>impairment</topic><topic>Injectable</topic><topic>mellitus</topic><topic>Older</topic><topic>Oral</topic><topic>people</topic><topic>Renal</topic><topic>Review</topic><topic>Treatment</topic><topic>treatments</topic><topic>Type</topic><toplevel>online_resources</toplevel><creatorcontrib>Juan Jose Marin-Penalver;Iciar Martin-Timon;Cristina Sevillano-Collantes;Francisco Javier del Canizo-Gomez</creatorcontrib><collection>维普_期刊</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of diabetes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Juan Jose Marin-Penalver;Iciar Martin-Timon;Cristina Sevillano-Collantes;Francisco Javier del Canizo-Gomez</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Update on the treatment of type 2 diabetes mellitus</atitle><jtitle>World journal of diabetes</jtitle><addtitle>World Journal of Diabetes</addtitle><date>2016-09-15</date><risdate>2016</risdate><volume>7</volume><issue>17</issue><spage>354</spage><epage>395</epage><pages>354-395</pages><issn>1948-9358</issn><eissn>1948-9358</eissn><abstract>To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving nearnormal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different treatments, both oral and injectable, available for the treatment of type 2 diabetes mellitus (T2DM). Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control. The aim of this review is to perform an update on the benefits and limitations of different drugs, both current and future, for the treatment of T2DM. Initial intervention should focus on lifesty lechanges. Moreover, changes in lifestyle have proven to be beneficial, but for many patients is a complication keep long term. Physicians should be familiar with the different types of existing drugs for the treatment of diabetes and select the most effective, safe and better tolerated by patients. Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized depending on thecharacteristics of each patient. This article reviews the treatments available for patients with T2DM, with an emphasis on agents introduced within the last decade.</abstract><cop>United States</cop><pub>Baishideng Publishing Group Inc</pub><pmid>27660695</pmid><doi>10.4239/wjd.v7.i17.354</doi><tpages>42</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1948-9358
ispartof World journal of diabetes, 2016-09, Vol.7 (17), p.354-395
issn 1948-9358
1948-9358
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5027002
source PMC (PubMed Central)
subjects agents
antidiabetic
diabetes
Future
impairment
Injectable
mellitus
Older
Oral
people
Renal
Review
Treatment
treatments
Type
title Update on the treatment of type 2 diabetes mellitus
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T00%3A33%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Update%20on%20the%20treatment%20of%20type%202%20diabetes%20mellitus&rft.jtitle=World%20journal%20of%20diabetes&rft.au=Juan%20Jose%20Marin-Penalver;Iciar%20Martin-Timon;Cristina%20Sevillano-Collantes;Francisco%20Javier%20del%20Canizo-Gomez&rft.date=2016-09-15&rft.volume=7&rft.issue=17&rft.spage=354&rft.epage=395&rft.pages=354-395&rft.issn=1948-9358&rft.eissn=1948-9358&rft_id=info:doi/10.4239/wjd.v7.i17.354&rft_dat=%3Cproquest_pubme%3E1823037043%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c348t-885b105121c581c520e8e2e5606c221752ebab7a8b107b2208f56581ac04efbe3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1823037043&rft_id=info:pmid/27660695&rft_cqvip_id=7000168841&rfr_iscdi=true